CCO Infectious Disease Podcast artwork

Investigational PPAR-delta Agonist for PBC Treatment and Race-Based Considerations for PBC Diagnosis: Conference Coverage of AASLD

CCO Infectious Disease Podcast

English - December 07, 2023 05:00 - 9 minutes - 8.56 MB
Courses Education Science Life Sciences hiv covid-19 cme hepatitis b hbv id medical education coronavirus hepatitis c hcv Homepage Download Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: Investigational Dual PPAR Agonist, FXR Agonist With Fibrate, and Hyperlipidemia in People With PBC: Conference Coverage of AASLD
Next Episode: CRE-ating Success: How I Use Rapid Diagnostic Tests to Manage Carbapenem-Resistant Enterobacterales Bacteremia

During the 2023 American Association of the Study of Liver Diseases (AASLD) conference, exciting and important results from many primary biliary cholangitis (PBC) clinical trials were reported, including 3 late-breaking studies on the PPAR-delta agonist seladelpar, the dual PPAR agonist elafibranor, and the combination of the FXR agonist obeticholic acid and a fibrate.

In this episode, Stuart C. Gordon, MD, FAASLD, discusses topline results from one of these late-breaking studies and more, including: 

A phase III study of an investigational PPAR-delta agonist (seladelpar) in people with PBC who had failed to respond to ursodeoxycholic acidA study that explored racial differences as they relate to the presentation and diagnosis of PBC

Presenter: 
Stuart C. Gordon, MD, FAASLD
Director of Hepatology
Henry Ford Health System
Professor of Medicine
Wayne State University School of Medicine
Detroit, Michigan

Link to commentary:
https://bit.ly/3GzRMt2

Link to reviews of other PBC studies from AASLD 2023:
https://bit.ly/3RvXXEI